The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti-depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago. In 2000, a pharmacokinetic interaction between SJW and cyclosporine caused acute rejection in two heart transplant patients.
.
SJW extracts contain numerous constituents belonging to at least 10 biologically active chemical classes (Nahrstedt & Butterweck, 2010) .
Major compounds are naphthodianthrones (such as hypericin), phloroglucinol derivatives (such as hyperforin), and flavonoids (such as quercetin, hyperoside, rutoside, miquelianin, and quercitrin; Figure 1 ).
Numerous SJW preparations are commercially available, and manufacturers employ various methods to produce and maintain uniformity for their products. However, the extraction process determines the composition of the final product. Hydroalcoholic extracts may contain up to 6% hyperforin (Pharm Eur, 01/2017:1874) which is not chemically stable and can degrade rapidly. In the past, the amount of hyperforin was neglected during the extraction process because of its instability, generating hydroalcoholic extracts that usually contained just 0.5-2% hyperforin. However, at the end of the 1990s, some manufacturers modified the extraction method to obtain extracts with hyperforin amounts of 4-5%, because, at that time, hyperforin was thought to be one of the main active compounds in SJW extracts. When the recommended daily dose of SJW is 900 mg (3 × 300 mg) is taken, this amount of the extract is equivalent to a daily dose of approximately 40 mg of hyperforin. Interestingly, along with the modified extraction method producing extracts with a high hyperforin content, first reports of clinically relevant drug interactions occurred. As extracts of natural product, in general, are of complex composition, it is likely that the analytical profile of SJW preparations will vary with the extraction method used. Hyperforin, hypericin, and flavonoids have been demonstrated to be present in very different concentrations in various commercial products. For example, a German study that analysed 33 different SJW products showed that the hyperforin content varied from <0.5 mg per unit (<0.2% of extract) to 13 mg per unit (approx. 4.3% of extract) while hypericin varied between 0.1% and 0.3% (Wurglics et al., 2001a; Wurglics et al., 2001b) . Similar results were reported by Länger (2010) , who compared the hyperforin and hypericin content of several commercial SJW extracts that were used in relevant clinical studies. The hyperforin content in these extracts varied from 0% to 6%; hypericin varied between 0.1% and 0.3%. In a recent study, Schäfer, Potterat, Seibert, Fertig, & Meyer zu Schwabedissen (2019) tested several commercial SJW extracts currently marketed in Switzerland and observed a clear association between the hyperforin content and the influence on their transactivating activity. Importantly, no such correlation was observed for hypericin content and pregnane X receptor (PXR)-mediated transactivation.
The general public perception that herbal-based medicinal products are safe was reinforced by studies showing fewer adverse events occurring with SJW preparations, being possibly even safer than conventional antidepressants (Beaubrun & Gray, 2000; Gaster, 2000; Linde, Berner, & Kriston, 2008; McIntyre, 2000) . However, the mood enhancement effect was similar to synthetic antidepressants (Philipp et al., 1999; Schrader, 2000; Schwarz & Cupp, 2000; Woelk, 2000) .
A European drug-monitoring study in 3,250 patients reported an overall adverse events incidence of only 2.4% for the clinical use of a commercial SJW extract in the treatment of depression (Woelk, Brukard, & Grunwald, 1994) . Undesirable effects that were most commonly reported were gastrointestinal irritations (0.6%), allergic reactions (0.5%), fatigue (0.4%), and restlessness (0.3%). A meta-analysis based on traditional SJW preparations revealed that when adverse reactions occur, they are generally mild, transient, and similar to placebo (Linde et al., 1996) . In a review of SJW preparations and their adverse drug reactions (ADR), the author noted that this incidence was some 10 times less than that for synthetic antidepressants (Schulz, 2002) . The most common adverse events (one per 300,000 treated cases) among the spontaneous reports in a German ADR recording system between October 1991 and December 1999 involved reactions of the skin exposed to light (27 incidents) that was followed by increased bleeding time with coumarin-type oral anticoagulants (16 reports), eight incidents of breakthrough bleeding with oral contraceptives, and seven reported decreases in cyclosporine concentrations in organ transplant recipients.
Further investigations in volunteers determined that photosensitisation occurred only when doses of 2-4 gÁday −1 of a commercial SJW preparation (equivalent to approximately 5-10 mg of the hypericin that causes this effect) were taken (Schulz, 2002) . Analysis of available epidemiological data showed that, although photosensitisation had the highest incidence of ADR reports, severe phototoxic reactions comparable to cases documented for grazing animals have never been reported in humans. The 27 phototoxicity reports relative to the incidence of sun exposure damage in the population do not warrant regulatory intervention. The significance of the eight reports of breakthrough bleeding during concomitant SJW and oral contraceptive therapy should be viewed in context with the estimated 4 million female treated patients of child bearing age and the 10-fold higher incidence of spontaneous breakthrough bleeding with low-dose oral oestrogens. However, the seven reports of decreased cyclosporine concentrations represent a much higher incidence of ADR in the relatively small transplant patient population (Schulz, 2002) . It was discussed at that time that cyclosporine concentrations could indicate dosage adjustment with therapeutic drug monitoring, and in these cases, the interaction would be considered clinically significant.
Since then, several case studies addressed the clinical significance of interactions between cyclosporine and SJW. Awareness of the clinical relevance of this interaction was raised after a liver allograft F I G U R E 1 Chemical structures of major compounds found in Hypericum perforatum (St. John's wort) extracts transplantation in a 63-year-old patient. Fourteen months after transplantation, this patient developed severe acute rejection, which was related with an unexpected decrease in cyclosporine levels. The patient had started taking an SJW preparation (2 × 900 mgÁday −1 ) for increasing episodes of depression 2 weeks prior to the transplantation.
The cyclosporine dosage was then increased, leading to ADRs. Finally, an assessment of oral cyclosporine absorption suggested enhanced cyclosporine metabolism. When SJW intake was discontinued, cyclosporine blood levels recovered (Karliova et al., 2000) . Two cases of acute heart transplant rejection that were associated with a specific SJW preparation emphasized the clinical significance of this drug interaction. In both cases, daily dosing with 900 mg of a commercial SJW extract preceded the decreased cyclosporine levels in previously stable patients and acute heart transplant rejection that was demonstrated by endomyocardial biopsy. Cyclosporine concentrations returned to therapeutic range when patients discontinued SJW ingestion (Ruschitzka, Meier, Turina, Lüscher, & Noll, 2000) . Nearly identical scenarios were described in two separate case reports for renal transplant patients that had subtherapeutic concentrations of cyclosporine associated with ingesting SJW preparations at recommended doses (Mai et al., 2000; Moschella & Jaber, 2001) . In both cases, cyclosporine concentrations returned to normal after discontinuing SJW.
It is noteworthy to mention that for all of the cases where clinical relevant pharmacokinetic interactions occurred, SJW preparations were involved that were rich in hyperforin. For products that contain low-hyperforin contents, no clinically relevant pharmacokinetic drug interaction has been reported (Table 1 ; Arold et al., 2005; Mai et al., 2004; Müller et al., 2004; Müller et al., 2006; Müller et al., 2009; Will-Shahab, Bauer, Kunter, Roots, & Brattström, 2009; Zahner et al., 2019 (Müller et al., 2004) Note. No clinically relevant interactions could be found at indicated low daily doses of hyperforin. Abbreviations: C max , maximum plasma concentration; CYP, cytochrome P450 enzyme, P-gp, P-glycoprotein; t 1/2 , eliminiation t 1/2 ; t max , time to reach C max .
| IN VITRO AND IN VIVO PHARMACOLOGICAL MECHANISMS CONTRIBUTING TO THE CLINICAL EFFICACY OF SJW
Up to now, it is impossible to attribute the various pharmacological effects of SJW to the action of single constituents. Therefore, the single compounds of the extract may be regarded to act synergistically (Schmidt & Butterweck, 2015) . The extract is considered to be the pharmacological principle, and thus, SJW extracts are classified as The effect of SJW extract on β-adrenoceptors was first studied by the group of Müller, Rolli, Schäfer, and Hafner (1997) who showed that the number of rat cortical β-adrenoceptors was down-regulated after treatment with an SJW extract, while no change in receptor affinity was observed. Kientsch et al. (2001) demonstrated that chronic exposure of an extract, devoid of hyperforin, dosedependently down-regulated the number of β-adrenoceptors in C6 cells, comparable to desipramine. In vivo, a SJW extract reduced the number of β-adrenoceptors in rat frontal cortex (Simbrey, Winterhoff, & Butterweck, 2004 ).
• As observed for 5-HT reuptake inhibitors (SSRI) and tricyclic antidepressants, re-uptake inhibition of monoamine neurotransmitters was observed in synaptosomal preparations, brain slices, or neuronal cells (Chatterjee, Bhattacharya, Wonnemann, Singer, & Muller, 1998; Jensen, Hansen, & Nielsen, 2001; Kientsch et al., 2001; Müller et al., 1998; Neary & Bu, 1999; Perovic & Müller, 1995; Ruedeberg, Wiesmann, Brattstroem, & Honegger, 2010; Wonnemann, Singer, Siebert, & Müller, 2001) . To explain the mechanism of re-uptake inhibition, effects of SJW extracts on transporters were investigated. Gobbi et al. (1999) found no interaction of an SJW extract with serotonin transporters and explained the re-uptake inhibitory effects with a reserpine-like mechanism. Singer, Wonnemann, and Müller (1999) postulated that the re-uptake inhibition of SJW extract was due to a nonselective increase in free intracellular sodium concentrations. In vivo, acute and long-term administration increased brain monoamine neurotransmitter content in the rat cortex after treatment with an SJW extract (Butterweck, Bockers, Korte, Wittkowski, & Winterhoff, 2002 ).
• Acute immobilization stress following 8 weeks of SJW extract administration decreased mRNA levels of brain-derived neurotrophic factor selectively in the rat dentate gyrus (Butterweck, Winterhoff, & Herkenham, 2001) . Similar results were observed by Valvassori et al. (2018) who also reported that SJW decreased brain-derived neurotrophic factors in the rat hippocampus.
• In several neuropsychiatric diseases, including major depression, elevated inflammatory cytokine levels were observed (Miller, Maletic, & Raison, 2009) , where microglia seem to be a primary source of brain cytokines. in vitro inhibition of cytokine release was inhibited in PHA/LPS-stimulated hippocampal HT22 cells (Bonaterra et al., 2018; Thiele, Brink, & Ploch, 1994 ). An SJW extract also protected rat and human pancreatic islets against cytokine toxicity (Novelli et al., 2014) . Furthermore, SJW reduced paracetamol-induced cytokine production in male Swiss mice (Hohmann et al., 2015) .
As a hyperactivity of the hypothalamic-pituitary-adrenal axis appears to be involved in depression (Arborelius, Owens, Plotsky, & Nemeroff, 1999) , several investigations showed modulating effects of SJW extracts on this axis (Butterweck, Winterhoff, & Herkenham, 2003; Butterweck et al., 2001 ). Short-and long-term administration of an SJW extract to rats reduced the expression of genes that are involved in the regulation of the hypothalamic-pituitary-adrenal axis and lowered plasma adrenocorticotropic hormone and corticosterone levels.
• Verjee, Weston, Kolb, Kalbhenn-Aziz, and Butterweck (2018) showed in recent in vitro experiments that the SSRI citalopram as well as a commercial SJW extract could antagonize the dexamethasone stress-induced increase in expression of the mRNA for
FK506-binding protein 51 (FKBP5). FKBP5 is a co-chaperone involved in the translocation of the glucocorticoid receptor (GR).
Activation of GR leads to an up-regulation of FKBP5 mRNA, which then provides an ultra-short negative feedback loop for GR sensitivity. FKBP5 has been shown to play an important role in several mental disorders and stress-related conditions (Menke, 2019) .
• Recently, an SJW extract containing low amounts of hyperforin was investigated for its effect on plasma membrane fluidity in rat C6 glioblastoma cells (Keksel et al., 2019) . Cortisol, which is increasingly formed under chronic stress conditions, is raising plasma membrane fluidity (Arborelius et al., 1999; Chrousos, 2009) . SJW reversed the cortisol-induced changes completely. In addition, cortisol and the structurally related substance dexamethasone were shown to influence the concentration of cholesterol in cellular membranes. These changes in membrane composition and properties affect membrane-embedded receptors like the β 1 -adrenoceptor (ADRB1), leading to slower receptor mobility (Jakobs et al., 2013; Prenner, Sieben, Zeller, Weiser, & Häberlein, 2007) . Appropriate to this are findings showing that under repeated SJW extract treatment, a lower activation of β 1 -adrenoceptors is observed, indicated by a reduced cAMP formation. Therefore, it may be suggested that SJW not only affects the membrane fluidity of neuronal cells but also affects the lateral mobility of membrane-associated receptors, which subsequently may normalize signal transduction processes in stress-related diseases such as depression (Keksel et al., 2019) .
| BEHAVIOURAL PHARMACOLOGY RELATED TO ANTIDEPRESSANT EFFECTS
The antidepressant effects of SJW extracts have been tested and con- . The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.
Several studies also demonstrated that various SJW extracts could reduce stress-induced behavioural deficits in the learned helplessness test (Bhattacharya, Chakrabarti, & Chatterjee, 1998; Chatterjee et al., 1998; Gambarana et al., 1999; Scheggi et al., 2016) . The effect on cognition ability was tested in Barnes maze or Morris water maze. SJW alleviated stress and corticosterone related memory impairments (Trofimiuk & Braszko, 2008; Trofimiuk, Holownia, & Braszko, 2011 ).
In conclusion, a variety of behavioural studies have been per- Therefore, SJW is a prime example of the entire extract being defined as the active constituent.
| CLINICAL EFFICACY ACHIEVED WITH LOW DAILY DOSES OF SJW EXTRACT OR HYPERFORIN
The contribution of hyperforin to the clinical efficacy of SJW extracts has been a matter for considerable debate. Initially, the component was suggested as the major active principle of SJW leading to antidepressant effects . However, clinical efficacy has also been demonstrated with low-hyperforin SJW extracts (Schrader, 2000; Schrader et al., 1998; Woelk, 2000) . When Therefore, in line with its regulatory specification as a "quantified extract," the whole extract has to be seen as a single active pharmaceutical ingredient contributing to clinical efficacy in the treatment of depressive disorders (Schmidt & Butterweck, 2015) .
| LIGAND-MEDIATED PXR ACTIVATION-THE MECHANISM UNDERLYING THE DRUG-INTERACTION POTENTIAL OF ST. JOHNS' WORT
It was shortly after the first reports on single cases of SJW being asso- (Zanger & Schwab, 2013) .
Among the 57 putatively functional human CYPs, CYP3A4 but also CYP2C9, CYP2C8, CYP2E1, and CYP1A2 are most highly expressed in liver, covering a large spectrum of chemical entities handled in metabolism (Zanger & Schwab, 2013) . Moreover, Moore et al. (2000) tested several constituents of SJW and showed that hyperforin was the most likely driver of the PXR transactivation, with a K i of 27 nM.
In been recently shown for PXR transactivation, using hepatoma cells for heterologous expression (Schäfer et al., 2019) .
The PXR is a member of the family of nuclear receptors and is involved in the regulation of metabolic processes in response to xenobiotics (Pascussi, Gerbal-Chaloin, Drocourt, Maurel, & Vilarem, 2003) .
It exhibits a ligand-binding domain and a DNA-binding domain and acts as a ligand-activated transcription factor after heterodimerizing with the retinoid X receptor (Evans & Mangelsdorf, 2014; Hyrsova et al., 2019; Moore et al., 2000) .
Based on a PXR pharmacophore model developed by Ekins and Erickson (2002) , hypericin, the second presumably active ingredient of SJW, would be classified as potential, but non-potent, activator of the human PXR. However, experimental data show that there is no significant transactivation in cells exposed to hypericin (Moore et al., 2000) . shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Schäfer, Bock, & Meyer Zu Schwabedissen, 2018) , thus influencing the intracellular transactivation of PXR by hyperforin (Schäfer et al., 2019) . Importantly, OATP2B1 is expressed not only in human hepatocytes but also in enterocytes (Kobayashi et al., 2003) , and cells of the renal tubule (Ferreira et al., 2018) , where it is assumed to influence oral drug absorption and renal elimination. Interaction with hyperforin may therefore be not only limited to metabolized substrates but may even be extended.
| DETAILS ON THE REGULATION OF DRUG TRANSPORTERS BY PXR
For the efflux transporters, and especially for ABCB1 (P-glycoprotein) and ABCC2 (MRP2), they are known to be transcriptionally regulated by PXR (Geick, Eichelbaum, & Burk, 2001; Kast et al., 2002; Martin, Riley, Back, & Owen, 2008; Oscarson et al., 2006) . ABCC2
induction by hyperforin has been reported in human hepatoma cells (Grewal et al., 2017) . Similar results were obtained testing the influence of rifampicin in isolated and cultured human hepatocytes (Jigorel, Le Vee, Boursier-Neyret, Parmentier, & Fardel, 2006; Martin et al., 2008) . However, it seems noteworthy that expression and transcriptional functionality of PXR in HepG2 cells is much lower than in isolated human hepatocytes (Martin et al., 2008) , suggesting that the observed hyperforin-associated increase in expression may even be more pronounced. ABCC2 is localized in the canalicular membrane of hepatocytes, where it mediates biliary elimination of various compounds (Konig, Nies, Cui, Leier, & Keppler, 1999) . Furthermore, ABCC2 is assumed to be a key determinant in the transmembrane transport of phase II metabolites, although its substrate spectrum is not limited to those metabolites (Fardel, Jigorel, Le Vee, & Payen, 2005) . Accordingly, induction of ABCC2 appears to mechanistically and functionally be linked to the enhanced expression and activity of UGTs. A similar mechanistic link is assumed for CYP3A4 and ABCB1 (Kim et al., 1999) .
It is assumed that modulation of ABCB1 by PXR is tissue specific, with pronounced changes in enterocytes, but only limited effects in F I G U R E 3 Hyperforin-dependent mechanism underlies the pharmacokinetic interactions of St. John's wort. ABCB1, ATP-binding cassette subfamily B member 1; CAR, constitutive active receptor; CYP3A4, cytochrome P450 enzyme 3A4; OATP, organic anion transporting polypetide; PXR, pregnane X receptor; PXRRE, pregnane X response element; RXR, retinoid X receptor; SULT, sulfotransferase liver in vivo. In detail, Haslam, Jones, Coleman, and Simmons (2008) reported induction of ABCB1 (MDR1) (Bauer, Hartz, Fricker, & Miller, 2004 ). An increase in ABCB1 expression in brain capillaries has also been shown in mice (transgenic for Alzheimer's disease) after 120 days exposure to SJW extracts (Brenn et al., 2014) . It is important to mention, in this context, that there is only limited transactivation of the rat PXR by hyperforin, which is significantly enhanced after exchanging the amino acid F305 for leucine (Tirona, Leake, Podust, & Kim, 2004) . Accordingly, data reporting on hyperforin effects in rodent models have to be carefully and function in capillaries of pigs (Ott, Fricker, & Bauer, 2009 ).
Moreover, using porcine brain capillary endothelial cells, Ott, Huls, Cornelius, and Fricker (2010) showed that short term exposure to SJW extracts (unknown) or the constituents hyperforin, hypericin, and quercetin (at higher concentrations) inhibited calcein-efflux function and most likely via ABCB1 (P-glycoprotein). Finally, using a transgenic mouse model expressing the human isoform of the nuclear receptor, Bauer et al. showed that hyperforin treatment in vitro significantly enhances the expression of ABCB1 (P-glycoprotein) in brain capillaries. Even if not tested with hyperforin, they were able to show that pretreatment with the PXR-inducer rifampicin significantly reduced the antinociceptive effect of methadone in mice, even if this treatment did not significantly change the plasma levels of the compound (Bauer et al., 2006) . Taken together, it may even be expected that the SJW constituent hyperforin influences the functionality of the blood-brain barrier, thereby enhancing CNS entry of molecules.
| CLINICALLY RELEVANT DRUG INTERACTIONS OF SJW DEPEND ON THE HYPERFORIN DOSE
As mentioned earlier, pharmacokinetic interactions with CYP3A4-metabolized and/or P-gp-transported drugs were reported in cases of acute heart transplant and liver rejection in cyclosporinetreated patients (Karliova et al., 2000; Ruschitzka et al., 2000) but also in cases of breakthrough bleedings and unwanted pregnancies despite oral contraceptives (Bon, Hartmann, & Kuhn, 1999; Hall et al., 2003; Pfrunder et al., 2003; Schwarz, Buschel, & Kirch, 2003) . Further, publications on altered digoxin, theophylline, phenprocoumon, and indinavir plasma concentrations were part of the prime safety signals in association with SJW in 1999 (Bon et al., 1999; Cheng, 2000; Johne et al., 1999; Nebel, Schneider, Baker, & Kroll, 1999; Piscitelli, Burstein, Chaitt, Alfaro, & Falloon, 2000) . These reports are likely to be the result of the change in extraction procedure triggered by the assumption that hyperforin contributes to the clinical efficacy of SJW Madabushi, Frank, Drewelow, Derendorf, & Butterweck, 2006) . As a consequence, for SJW products registered as (Zahner et al., 2019) . As a consequence, convincing clinical evidence prompted the Swiss Agency for Therapeutic Products (Swissmedic) to be the first regulatory authority to approve the removal of contraindications, warnings, and pharmacokinetic interactions for a low-hyperforin herbal medicinal product.
Taken together, data on the pharmacokinetic interactions with SJW preparations correlate directly with the daily dose of hyperforin (Müller et al., 2006) . The induction of PXR-related metabolic enzymes and transporters cannot be excluded at daily dosages >1-mg hyperforin. To avoid pharmacokinetic interactions and to contribute to SJW product safety, low-hyperforin SJW extracts should be recommended for therapeutic use. At daily dosages of maximum 1-mg hyperforin, no clinically relevant pharmacokinetic interactions are to be expected (EMA/HMPC, 2018; ESCOP, 2018; Zahner et al., 2019) .
| CONCLUSIONS
In summary, 20 years after the first reports of clinically relevant drug interactions with SJW extracts, it is clear that, in order to reduce or avoid the risk of pharmacokinetic drug interactions of prescribed medicines with preparations of SJW, the use of quantified extracts with a low-hyperforin content is recommended. Up to a maximum daily dose of 1-mg hyperforin, no clinically relevant interactions are to be expected.
On the other hand, to make use of the hyperforin-dependent induction of PXR-related metabolic enzymes and transport systems, high-hyperforin SJW extracts should be further investigated as medications. This could either be for clinical purposes such as treatment of
Crigler-Najjar-Syndrome type II or in pharmacokinetic interaction studies as inducer of CYP3A4, P-gp, or UGTs.
Importantly, as recommended by the EMA in 2009, the amount of hyperforin should be declared for medicinal products containing SJW. Unfortunately, even for herbal medicinal products, this safetyrelevant recommendation is rarely followed and is completely neglected in botanicals and food/dietary supplements. Also, in clinical pharmacokinetic studies and case reports, the administered SJW products were often lacking sufficient specifications (herbal drug substance or extract, drug-extract ratio, solvent), especially regarding the hyperforin content. The ongoing use of high-hyperforin SJW products among botanicals and food/dietary supplements explains why an unnecessary safety risk for pharmacokinetic drug interactions persists in the public, despite labelling and warnings. This fact highlights also the importance of clinical and analytical comparison studies among different SJW preparations to provide information on hyperforin content of considerably safer products. Therefore, to avoid unnecessary drug safety risks in co-medication therapy, low-hyperforin SJW extracts should be prescribed to patients suffering from depressive episodes. Currently, the recommended daily intake of SJW varies between 180 and 1800 mg. As higher doses of SJW do not lead to a more pronounced decrease of depressive symptoms, SJW products with lower extract doses should be preferentially recommended to avoid further safety risks.
In countries with regulations of SJW status other than a registered drug, herbal medicinal product or traditional herbal medicinal product, awareness should increase among physicians regarding hyperforin as dose-dependent inducer of cytochrome P450 enzymes (e.g., CYP3A4), transporters (e.g., P-gp, OATP1A2), and other PXRrelated targets.
To avoid the risk of unnecessary pharmacokinetic interactions with SJW, a safety threshold of maximum 1-mg hyperforin per day is recommended.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY (Harding et al., 2018) and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Christopoulos et al., 2019; Alexander, Cidlowski et al., 2019; Alexander, Fabbro et al., 2019; . 
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